Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ING-1
- Development stage
- Phase 1
- Lead developer
- XOMA
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
ING-1 is a human-engineered monoclonal antibody developed to target the epithelial cell adhesion molecule (EpCAM), also known as CD326. EpCAM is highly expressed on many adenocarcinoma tumor cells. The drug was designed as an anti-tumor agent and has been investigated for use in various cancers, particularly adenocarcinomas such as breast, colorectal, lung, ovary, and prostate cancer. Its mechanism of action involves binding to EpCAM on tumor cells; in some investigational approaches (such as with Triton's Targeted Nano-Therapeutics System), it may be used to deliver tiny magnetic spheres that can be heated by an external magnetic field to ablate tumors selectively[1][2][3]. Clinical development reached Phase 1 trials for advanced adenocarcinomas.
- Other names
- anti-Ep-CAM monoclonal antibody ING-1heMAb
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on ING-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ING-1.